Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model.

Niyazi M, Niemierko A, Paganetti H, Söhn M, Schapira E, Goldberg S, Adams J, Kim V, Oh KS, Hwang WL, Lu HM, Belka C, Busse PM, Loeffler JS, Shih HA.

Radiother Oncol. 2019 Sep 25. pii: S0167-8140(19)33092-0. doi: 10.1016/j.radonc.2019.09.008. [Epub ahead of print]

PMID:
31563411
2.

ACR Appropriateness Criteria® Neck Mass-Adenopathy.

Expert Panel on Neurologic Imaging:, Aulino JM, Kirsch CFE, Burns J, Busse PM, Chakraborty S, Choudhri AF, Conley DB, Jones CU, Lee RK, Luttrull MD, Moritani T, Policeni B, Ryan ME, Shah LM, Sharma A, Shih RY, Subramaniam RM, Symko SC, Bykowski J.

J Am Coll Radiol. 2019 May;16(5S):S150-S160. doi: 10.1016/j.jacr.2019.02.025.

PMID:
31054741
3.

Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, Patel KB, Hayes DN, Glomski K, Busse PM, Chan AW, Clark JR, Deschler DG, Emerick KS, Hammon RJ, Wirth LJ, Lin DT, Mroz EA, Faquin WC, Rocco JW.

J Natl Cancer Inst. 2019 Sep 1;111(9):933-942. doi: 10.1093/jnci/djy224.

PMID:
30715409
4.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

5.

Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation.

Frank SJ, Blanchard P, Lee JJ, Sturgis EM, Kies MS, Machtay M, Vikram B, Garden AS, Rosenthal DI, Gunn GB, Fuller CD, Hutcheson K, Lai S, Busse PM, Lee NY, Lin A, Foote RL.

Semin Radiat Oncol. 2018 Apr;28(2):108-113. doi: 10.1016/j.semradonc.2017.12.002.

6.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

7.

Definitive proton beam therapy for adenoid cystic carcinoma of the nasopharynx involving the base of skull.

Gentile MS, Yip D, Liebsch NJ, Adams JA, Busse PM, Chan AW.

Oral Oncol. 2017 Feb;65:38-44. doi: 10.1016/j.oraloncology.2016.11.016. Epub 2016 Dec 23.

PMID:
28109466
8.

ACR appropriateness criteria® nasal cavity and paranasal sinus cancers.

Siddiqui F, Smith RV, Yom SS, Beitler JJ, Busse PM, Cooper JS, Hanna EY, Jones CU, Koyfman SA, Quon H, Ridge JA, Saba NF, Worden F, Yao M, Salama JK; Expert Panel on Radiation Oncology - Head and Neck Cancer.

Head Neck. 2017 Mar;39(3):407-418. doi: 10.1002/hed.24639. Epub 2016 Dec 29. Review.

9.

ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas.

Beitler JJ, Quon H, Jones CU, Salama JK, Busse PM, Cooper JS, Koyfman SA, Ridge JA, Saba NF, Siddiqui F, Smith RV, Worden F, Yao M, Yom SS; Expert Panel on Radiation Oncology - Head and Neck.

Head Neck. 2016 Sep;38(9):1299-309. doi: 10.1002/hed.24447. Epub 2016 Jun 22. Review.

10.

ACR Appropriateness criteria® for nasopharyngeal carcinoma.

Saba NF, Salama JK, Beitler JJ, Busse PM, Cooper JS, Jones CU, Koyfman S, Quon H, Ridge JA, Siddiqui F, Worden F, Yao M, Yom SS; Expert Panel on Radiation Oncology-Head and Neck Cancer.

Head Neck. 2016 Jul;38(7):979-86. doi: 10.1002/hed.24423. Epub 2016 Apr 30. Review.

PMID:
27131050
11.

Long-Term Outcomes After Proton Beam Therapy for Sinonasal Squamous Cell Carcinoma.

Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, Deschler DD, Lin DT, Delaney TF, Chan AW.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):368-76. doi: 10.1016/j.ijrobp.2016.02.042. Epub 2016 Feb 18.

PMID:
27084654
12.

ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck.

Koyfman SA, Cooper JS, Beitler JJ, Busse PM, Jones CU, McDonald MW, Quon H, Ridge JA, Saba NF, Salama JK, Siddiqui F, Smith RV, Worden F, Yao M, Yom SS.

Head Neck. 2016 Feb;38(2):175-82. doi: 10.1002/hed.24171.

13.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

14.

Proton therapy for pediatric and adolescent esthesioneuroblastoma.

Lucas JT Jr, Ladra MM, MacDonald SM, Busse PM, Friedmann AM, Ebb DH, Marcus KJ, Tarbell NJ, Yock TI.

Pediatr Blood Cancer. 2015 Sep;62(9):1523-8. doi: 10.1002/pbc.25494. Epub 2015 Mar 27.

PMID:
25820437
15.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

16.

Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership.

Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):468-75. doi: 10.1016/j.ijrobp.2014.03.033.

17.

Long-term survival after distant metastasis in patients with oropharyngeal cancer.

McBride SM, Busse PM, Clark JR, Wirth LJ, Ancukiewicz M, Chan AW.

Oral Oncol. 2014 Mar;50(3):208-12. doi: 10.1016/j.oraloncology.2013.10.020. Epub 2013 Dec 31.

PMID:
24387975
18.

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):917-23. Erratum in: J Natl Compr Canc Netw. 2013 Dec 1;11(12):1458.

PMID:
23946171
19.

Intensity-modulated versus conventional radiation therapy for oropharyngeal carcinoma: long-term dysphagia and tumor control outcomes.

McBride SM, Parambi RJ, Jang JW, Goldsmith T, Busse PM, Chan AW.

Head Neck. 2014 Apr;36(4):492-8. doi: 10.1002/hed.23319. Epub 2013 Jun 1.

PMID:
23729221
20.

Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer.

Nichols AC, Finkelstein DM, Faquin WC, Westra WH, Mroz EA, Kneuertz P, Begum S, Michaud WA, Busse PM, Clark JR, Rocco JW.

Clin Cancer Res. 2010 Apr 1;16(7):2138-46. doi: 10.1158/1078-0432.CCR-09-3185. Epub 2010 Mar 16.

21.

Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.

Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB.

Ann Oncol. 2010 Feb;21(2):342-7. doi: 10.1093/annonc/mdp477. Epub 2009 Nov 5.

PMID:
19892746
22.

Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer.

Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):725-33. doi: 10.1016/j.ijrobp.2008.11.059. Epub 2009 Apr 11.

PMID:
19362781
23.

Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.

Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW.

Clin Cancer Res. 2009 Mar 1;15(5):1645-54. doi: 10.1158/1078-0432.CCR-08-2581. Epub 2009 Feb 24.

24.

Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.

Lawenda BD, Arnold MG, Tokarz VA, Silverstein JR, Busse PM, McIntyre JF, Deschler DG, Baldini EH, Kachnic LA.

Ear Nose Throat J. 2008 Nov;87(11):634-43. Review.

PMID:
19006065
25.

Functional and histological changes in rat lung after boron neutron capture therapy.

Kiger JL, Kiger WS 3rd, Riley KJ, Binns PJ, Patel H, Hopewell JW, Harling OK, Busse PM, Coderre JA.

Radiat Res. 2008 Jul;170(1):60-9. doi: 10.1667/RR1266.1.

PMID:
18582158
26.

Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma.

Busse PM, Clark JR, Muse VV, Liu V.

N Engl J Med. 2008 Jun 19;358(25):2717-23. doi: 10.1056/NEJMcpc0803063. No abstract available.

PMID:
18565865
27.

Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.

Tishler RB, Posner MR, Norris CM Jr, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case M, Stowell S, Sammartino D, Busse PM, Haddad RI.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1036-44. Epub 2006 May 6.

PMID:
16682134
28.

Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach.

Haddad RI, Posner MR, Busse PM, Norris CM Jr, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB.

Am J Clin Oncol. 2006 Apr;29(2):153-7.

PMID:
16601434
29.

Pathology quiz case 1. Adenocarcinoma with features of mucinous adenocarcinoma (MAC) and cystadenocarcinoma (CAC).

Emerick KS, Mehta A, Pilch BZ, Deschler DG, Busse PM, Rocco JW.

Arch Otolaryngol Head Neck Surg. 2005 Dec;131(12):1120, 1122-3. No abstract available.

PMID:
16365230
30.

Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.

Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R.

Am J Clin Oncol. 2005 Aug;28(4):371-8.

PMID:
16062079
31.

Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base.

Karakoyun-Celik O, Norris CM Jr, Tishler R, Mahadevan A, Clark JR, Goldberg S, Devlin P, Busse PM.

Head Neck. 2005 May;27(5):353-61.

PMID:
15726587
32.

Preliminary treatment planning and dosimetry for a clinical trial of neutron capture therapy using a fission converter epithermal neutron beam.

Kiger WS 3rd, Lu XQ, Harling OK, Riley KJ, Binns PJ, Kaplan J, Patel H, Zamenhof RG, Shibata Y, Kaplan ID, Busse PM, Palmer MR.

Appl Radiat Isot. 2004 Nov;61(5):1075-81.

PMID:
15308195
33.

Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up.

Devlin PM, Kazakin J, Adak S, Li Y, Norris CM, Tishler RB, Clark JR, Busse PM, Posner MR.

Am J Clin Oncol. 2004 Aug;27(4):369-75.

PMID:
15289730
34.

The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma.

Kabalka GW, Nichols TL, Smith GT, Miller LF, Khan MK, Busse PM.

J Neurooncol. 2003 Mar-Apr;62(1-2):187-95.

PMID:
12749713
35.

Pharamacokinetic modeling for boronophenylalanine-fructose mediated neutron capture therapy: 10B concentration predictions and dosimetric consequences.

Kiger WS 3rd, Palmer MR, Riley KJ, Zamenhof RG, Busse PM.

J Neurooncol. 2003 Mar-Apr;62(1-2):171-86.

PMID:
12749712
36.

A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease.

Busse PM, Harling OK, Palmer MR, Kiger WS 3rd, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu XQ, Zamenhof RG.

J Neurooncol. 2003 Mar-Apr;62(1-2):111-21.

PMID:
12749707
37.

A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.

Tishler RB, Norris CM Jr, Colevas AD, Lamb CC, Karp D, Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, Costello R, Case M, Posner MR.

Cancer. 2002 Oct 1;95(7):1472-81.

38.

Treatment planning and dosimetry for the Harvard-MIT Phase I clinical trial of cranial neutron capture therapy.

Palmer MR, Goorley JT, Kiger WS, Busse PM, Riley KJ, Harling OK, Zamenhof RG.

Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1361-79.

PMID:
12128139
39.

A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans.

Kiger WS 3rd, Palmer MR, Riley KJ, Zamenhof RG, Busse PM.

Radiat Res. 2001 Apr;155(4):611-8.

PMID:
11260663
40.

The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.

Posner MR, Johnston PG, Tishler RB, Andersen J, Fiorentino M, Busse PM, Cavacini LA, Colevas AD, Clark J, Norris CM.

Oncologist. 1998;3(6):424-431.

41.

An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies.

Tishler RB, Busse PM, Norris CM Jr, Rossi R, Poulin M, Thornhill L, Costello R, Peters ES, Colevas AD, Posner MR.

Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1001-8.

PMID:
10192347
42.

Induction therapy for rectal carcinoma.

Busse PM, Ng A, Recht A.

Semin Surg Oncol. 1998 Sep;15(2):120-5. Review.

PMID:
9730418
43.

Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.

Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR.

J Clin Oncol. 1998 Apr;16(4):1331-9.

PMID:
9552034
44.

Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes.

Wong JS, Recht A, Beard CJ, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos TI, Nixon AJ, Shulman LN, Troyan S, Silver B, Harris JR.

Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):915-20. Review.

PMID:
9369141
45.

Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.

Clark JR, Busse PM, Norris CM Jr, Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, Colevas AD, Tishler RB, Costello R, Lucarini JW, Lucarini D, Thornhill L, Lackey M, Peters E, Posner MR.

J Clin Oncol. 1997 Sep;15(9):3100-10.

PMID:
9294473
46.

Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy.

Kim HK, Jessup JM, Beard CJ, Bornstein B, Cady B, Stone MD, Bleday R, Bothe A Jr, Steele G Jr, Busse PM.

Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):777-83.

PMID:
9240646
47.

Sphincter preservation therapy for distal rectal carcinoma: a review.

Ng AK, Recht A, Busse PM.

Cancer. 1997 Feb 15;79(4):671-83. Review.

PMID:
9024704
48.

Docetaxel: an active drug for squamous cell carcinoma of the head and neck.

Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR.

J Clin Oncol. 1996 May;14(5):1672-8.

PMID:
8622087
49.

Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.

Buswell L, Recht A, Clark J, Ravikumar T, Busse PM, Coleman CN.

Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):535-40.

PMID:
8005812
50.

Primary site management following induction chemotherapy with cis-platinum, 5-fluorouracil, and leucovorin.

Busse PM, Clark JR, Beard CJ, Dreyfuss AI, Lucarini JW, Rossi R, Casey D, Norris CM Jr.

Head Neck. 1993 Sep-Oct;15(5):413-8.

PMID:
8407313

Supplemental Content

Loading ...
Support Center